Iron status, inflammation and hepcidin in ESRD patients: The confounding role of intravenous iron therapy

Indian Journal of Nephrology

Volumn 20, Issue 3, 2010, Pages 125-131

  Jairam, A ^a   Das, R ^a   Aggarwal, P K ^a   Kohli, H S ^a   Gupta, K L ^a   Sakhuja, V ^a   Jha, V ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Anemia; end stage renal disease; hepcidin; inflammation; intravenous iron

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; FERRITIN; HEPCIDIN; INTERLEUKIN 6; IRON; PROHEPCIDIN; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALBUMIN BLOOD LEVEL; ANTHROPOMETRY; ARTICLE; BODY FAT; CLINICAL EXAMINATION; CONTROLLED STUDY; FEMALE; FERRITIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; INFLAMMATION; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; IRON STORAGE; IRON THERAPY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MUSCLE MASS; PROTEIN BLOOD LEVEL;

EID: 77958046563     PISSN: 09714065     EISSN: 19983662     Source Type: Journal    
DOI: 10.4103/0971-4065.70840     Document Type: Article

References (43)

1. KDOQI; National Kidney Foudnation. II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 2006;47:S16-85.
2. Collins AJ, Li S, Ebben J, Ma JZ, Manning W. Hematocrit levels and associated medicare expenditures. Am J Kidney Dis 2000;36:282-93.
3. MacDougall IC. Hyporesponsiveness to anemia therapy: What are we doing wrong? Perit Dial Int 2001;21:S225-30.
4. Kalantar-Zadeh K, Kopple JD, Humphreys MH, Block G. Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients. Nephrol Dial Transplant 2004;19:1507-19.
5. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of infammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 2004;19:141-9.
6. Feldman HI, Joffe M, Robinson B, Knauss J, Cizman B, Guo W, et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004;15:1623-32.
7. Chambers JC, Eda S, Bassett P, Karim Y, Thompson SG, Gallimore JR, et al. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation 2001;104:145-50.
8. Misra A. C-reactive protein in young individuals: Problems and implications for Asian Indians. Nutrition 2004;20:478-81.
9. Mehta BC. Iron defciency. Prevalence and problems. J Assoc Physicians India 1990;38:421-4.
10. Durnin JV, Womersley J. Body fat assessed from total body density and its estimation from skinfold thickness: Measurements on 481 men and women aged from 16 to 72 years. Br J Nutr 1974;32:77-97.
11. World Health organization: Techn Rep. Ser., No 702. 1984.
12. Barany P. Inflammation, serum C-reactive protein, and erythropoietin resistance. Nephrol Dial Transplant 2001;16:224-7.
13. (NFHS-II) NFHS-I: Anemia among women and children. Mumbai: International Institute for Population Sciences; 2002. p. 141-57.
14. Sheshadri S, editor. Nutritional anemia in South Asia. Kathmandu: UNICEF regional offce for South Asia; 1997.
15. Aggarwal HK, Nand N, Singh S, Singh M, Hemant, Kaushik G. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J Assoc Physicians India 2003;51:170-4.
16. Gupta M, Kannan M, Gupta S, Saxena R. Contribution of iron defciency to anemia in chronic renal failure. Indian J Pathol Microbiol 2003;46:563-4.
17. John GT, Chandy M, Thomas PP, Shastry JC, Jacob CK. Iron stores in patients on haemodialysis after renal transplantation. Natl Med J India 1993;6:108-10.
18. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition-infammation complex syndrome in dialysis patients: Causes and consequences. Am J Kidney Dis 2003;42:864-81.
19. Forouhi NG, Sattar N, McKeigue PM. Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int J Obes Relat Metab Disord 2001;25:1327-31.
20. Vikram NK, Misra A, Dwivedi M, Sharma R, Pandey RM, Luthra K, et al. Correlations of C-reactive protein levels with anthropometric profle, percentage of body fat and lipids in healthy adolescents and young adults in urban North India. Atherosclerosis 2003;168:305-13.
21. Macdougall IC, Cooper AC. Hyporesponsiveness to erythropoietic therapy due to chronic inflammation. Eur J Clin Invest 2005;35:32-5.
22. Cooper A, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Pentoxifylline improves hemoglobin levels in patients with erythropoietin- resistant anemia in renal failure. J Am Soc Nephrol 2004;15:1877-82.
23. Kulaksiz H, Gehrke SG, Janetzko A, Rost D, Bruckner T, Kallinowski B, et al. Pro-hepcidin: Expression and cell specifc localisation in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia. Gut 2004;53:735-43.
24. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001;276:7806-10.
25. Pietrangelo A, Trautwein C. Mechanisms of disease: The role of hepcidin in iron homeostasis-implications for hemochromatosis and other disorders. Nat Clin Pract Gastroenterol Hepatol 2004;1:39-45.
26. Malyszko J, Malyszko JS, Hryszko T, Pawlak K, Mysliwiec M. Is hepcidin a link between anemia, infammation and liver function in hemodialyzed patients? Am J Nephrol 2005;25:586-90.
27. Malyszko J, Malyszko JS, Mysliwiec M. Hyporesponsiveness to erythropoietin therapy in hemodialyzed patients: Potential role of prohepcidin, hepcidin, and infammation. Ren Fail 2009;31:544-8.
28. Memoli B, Salerno S, Procino A, Postiglione L, Morelli S, Sirico ML, et al. A translational approach to micro-infammation in end-stage renal disease: molecular effects of low levels of interleukin-6. Clin Sci (Lond) 2010;119:163-74.
29. Hsu SP, Chiang CK, Chien CT, Hung KY. Plasma prohepcidin positively correlates with hematocrit in chronic hemodialysis patients. Blood Purif 2006;24:311-6.
30. Kato A, Tsuji T, Luo J, Sakao Y, Yasuda H, Hishida A. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am J Nephrol 2008;28:115-21.
31. Shinzato T, Abe K, Furusu A, Harada T, Shinzato K, Miyazaki M, et al. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia. Med Sci Monit 2008;14:CR431-7.
32. Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, et al. Hepcidin: A potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1051-6.
33. Deicher R, Horl WH. Hepcidin: A molecular link between infammation and anaemia. Nephrol Dial Transplant 2004;19:521-4.
34. Garneata L. Intravenous iron, infammation, and oxidative stress: Is iron a friend or an enemy of uremic patients? J Ren Nutr 2008;18:40-5.
35. Agarwal R. Proinfammatory effects of iron sucrose in chronic kidney disease. Kidney Int 2006;69:1259-63.
36. Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004;65:2279-89.
37. Anirban G, Kohli HS, Jha V, Gupta KL, Sakhuja V. The comparative safety of various intravenous iron preparations in chronic kidney disease patients. Ren Fail 2008;30:629-38.
38. Ganguli A, Kohli HS, Khullar M, Lal Gupta K, Jha V, Sakhuja V. Lipid peroxidation products formation with various intravenous iron preparations in chronic kidney disease. Ren Fail 2009;31:106-10.
39. Maruyama Y, Nakayama M, Yoshimura K, Nakano H, Yamamoto H, Yokoyama K, et al. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels. Nephrol Dial Transplant 2007;22:1407-12.
40. Malyszko J, Malyszko JS, Mysliwiec M. Serum prohepcidin and hepcidin in hemodialyzed patients undergoing iron therapy. Kidney Blood Press Res 2009;32:235-8.
41. Zager RA, Johnson AC, Hanson SY, Lund S. Parenteral iron compounds sensitize mice to injury-initiated TNF-alpha mRNA production and TNF-alpha release. Am J Physiol Renal Physiol 2005;288:F290-7.
42. Weiss G, Meusburger E, Radacher G, Garimorth K, Neyer U, Mayer G. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int 2003;64:572-8.
43. Slotki I. Intravenous iron supplementation in the anaemia of renal and cardiac failure: A double-edged sword? Nephrol Dial Transplant 2005;20:716-23.